Tissue inflammation induces rapid mobilization of antigen-charged dendritic cells (DCs), which migrate to draining lymph nodes via afferent lymphatics to elicit the immune response. This increase in DC trafficking has been shown to require integrin-dependent adhesion to ICAM-1 and VCAM-1, expressed on inflamed lymphatic endothelium. In addition, both constitutive-and inflammationinduced DC migration involves the chemokine CCL21, which most likely triggers integrin activation on DC via its receptor CCR7. Recently, however, conflicting evidence has suggested that DC entry occurs independently of integrins, implying that the role of CCL21 in lymphatics is purely chemotactic. Hence, while CCL21 is reported to be inducible during inflammation, the details of this induction and the role of CCL21 during initial DC trafficking are unclear. Here, we have characterized both the production of CCL21 and the mechanism of its action in DC transmigration using primary human dermal lymphatic endothelial cells (HDLECs) and a mouse model of skin contact hypersensitivity. We showed that CCL21 is constitutively expressed intracellularly but rapidly secreted after exposure to the inflammatory cytokine tumour necrosis factor (TNF) a following de novo RNA and protein synthesis. Furthermore, using in vitro transmigration assays, we showed that endogenous HDLEC-derived CCL21 stimulates DC translymphatic migration by a predominantly chemotactic mechanism in resting HDLEC and by a b2 integrin-mediated mechanism in TNFa-stimulated HDLEC. These results imply a direct role for CCL21 in lymphatic transmigration that involves the selective use of integrin activation in inflammation.
Introduction
Both immature and semi-mature dendritic cell (DC) migrates continuously from tissues to lymph nodes through afferent lymphatics to maintain normal immune surveillance and peripheral tolerance (1) (2) (3) . The number of migrating cells increases dramatically during infection or inflammation, in response to bacterial endotoxins and classical proinflammatory cytokines such as IL-1 and tumour necrosis factor (TNF) a that induce maturation of DC from phagocytes to professional antigen-presenting cells (3) . This maturation leads to enhanced DC motility and responsiveness to chemokines such as CCL19 and CCL21 that are thought to guide migration of DC to their appropriate niches within the cortical T-cell zone of draining lymph nodes [reviewed in ref. (4) ]. One of the first steps in DC migration to the lymph nodes is exit from the tissues via the afferent lymphatics, a poorly understood process that involves transmigration across lymphatic vessel endothelium. Recently, we showed that lymphatic transmigration is an active process mediated by interactions of DC with the cell adhesion molecules (CAMs), ICAM-1 and vascular cell adhesion molecule (VCAM)-1, both of which are up-regulated on lymphatic endothelium in response to the inflammatory cytokines IL-1 and TNFa (5) . The importance of this adhesion axis is further underlined by the demonstration that immunizing mice with CAM-blocking mAbs substantially inhibits development of CD8 + T-cell responses in draining lymph nodes (6) , reviewed in ref. (7) .
The trafficking of DC in lymph is also dependent upon chemotaxis. Two chemokines in particular, CCL19 and CCL21, are implicated in lymph node homing through interactions with their common leucocyte receptor CCR7. Both CCL19 and CCL21 are produced by stromal cells within the T-cell zone of lymph nodes (8) (9) (10) . In addition, CCL21 is expressed by high endothelial venules (11) and lymphatic endothelium (12) . Evidence that CCL21 is critical for DC migration has come from the observation that 51 Cr-labelled DC injected into the footpads of mice failed to accumulate in draining lymph nodes when co-administered with CCL21-neutralizing antibodies (13) . At the same time, mice homozygous for the paucity of lymph node T-cell (plt) mutation (which was initially thought to ablate all expression of CCL21 and CCL19) exhibited defects in DC entry into the T-cell zone of lymph nodes (14) . From such studies, it was concluded that the basis for the defect was not an inability of DC to exit tissue through afferent lymphatics but some other step downstream of the process. Subsequent work has revealed that, in fact, mice express two functional isoforms of CCL21: CCL21 Ser , which is found in both peripheral and secondary lymphoid tissue and CCL21 Leu , which is found in peripheral tissues alone, within lymphatic endothelial cells (15, 16) . As the plt mutation disrupts expression of CCL21 specifically in lymphoid tissue, it has been assumed logically that CCL21
Ser regulates homing within lymph nodes and CCL21
Leu regulates DC entry to afferent lymphatics (16) . Additional evidence of a discrete role for CCL21 in regulating lymphatic entry has come from the observation that deletion of its receptor in CCR7 À/À mice causes retention of DC within the dermis and a failure to accumulate in dermal lymphatics, during both constitutive and inflammatory trafficking (17) . Based on the known mode of action of chemokines such as IL-8 (CXCL8) in the blood vasculature, one might assume that CCL21 would promote lymphatic entry by a mechanism of integrin-activated adhesion and transmigration (18) . However, recent experiments have reported the apparently normal entry of DC to afferent lymphatics in pan integrin-deficient mice, raising the possibility that the mode of action of CCL21 is predominantly chemotactic or pro-migratory (19) .
To compound the uncertainty regarding the mode of CCL21 action in DC trafficking, there is also ambiguity as to whether CCL21 is a constitutive or an inducible chemokine in lymphatic endothelium (12, 13, 20) . CCR7, the receptor for CCL21, is known to be up-regulated on DC during maturation, and hence, it has been assumed that the response to CCL21 is regulated at the level of receptor induction. Nevertheless, other reports allude to CCL21 induction in response to inflammation. The details of CCL21 expression in lymphatics would clearly benefit from a more rigorous analysis.
Here, we have carried out a study of CCL21 expression and function in the lymphatics, focusing mainly on lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) immunoselected primary human dermal lymphatic endothelial cells (HDLECs) (21) . Firstly, we show by a combination of fluorescence microscopy, flow cytometry and ELISA that CCL21 is stored within an intracellular compartment in resting HDLEC and that secretion is induced by exposure to the proinflammatory cytokine TNFa, following de novo RNA and protein synthesis. Secondly, we show that the capacity for control of CCL21 secretion is rapidly lost after passage of primary HDLEC in culture, resolving ambiguities in the recent literature and indicating the importance of the native tissue environment in maintaining this important physiological function. Thirdly, we showed using a defined in vitro assay that endogenous HDLEC-derived CCL21 directly promotes translymphatic migration of DC under both resting and inflammatory conditions but that only the latter pathway involves b2 integrin activation. These data further underline the importance of CCL21 for lymphatic entry and infer a role in initiating an adhesion-dependent pathway during inflammation.
Methods

Mice
BALB/c mice were maintained at the Biomedical Services Unit, John Radcliffe Hospital, Oxford, UK, and all studies were performed with appropriate UK Home Office licences according to established institutional guidelines.
Mouse dermal explants
Male BALB/c mice aged 8-10 weeks were euthanized by rising concentration of CO 2 . Ears were then removed, sterilized (30 min on ice) in PBS, pH 7.5, containing penicillin (5 U ml
À1
) and streptomycin (250 lg ml
), before splitting into dorsal and ventral halves and floating split-side (dermis) down in RPMI 1640, supplemented with 10% FCS, penicillin (1 U ml À1 ), streptomycin (50 lg ml
) and 2 mM L-glutamine. Explants were cultured in a humidified atmosphere at 37°C in 5% CO 2 in the presence of recombinant murine TNFa (100 ng ml
; R&D Systems).
Oxazolone-induced contact hypersensitivity
Male BALB/c mice aged 8-10 weeks were sensitized by topical application of 3% (w/v) oxazolone (4-ethoxymethylene-2 phenyl-2-oxazoline-5-one; Sigma-Aldrich) in 95% aqueous ethanol to the shaved abdomen (50 ll per mouse). The following day, a further 100 ll of 2.5% (w/v) oxazolone was applied to the same site. On day 5, the dorsal surface of the left ear was challenged in each case by topical application of 0.5% oxazolone solution (50 ll per ear), while the right ear (control) was treated with vehicle alone. Mice were sacrificed and ears were removed for whole-mount immunostaining 24 h later.
Immunofluorescence staining and confocal microscopy of whole-mount tissue sections Tissues were fixed for 2 h at 4°C in PFA (1% w/v in PBS, pH 7.4), blocked in PBS-Triton X-100 (0.3% v/v), supplemented with dried milk powder (3% w/v) and incubated with goat anti-CCL21 (R&D Systems), hamster anti-podoplanin (University of Iowa Hybridoma Bank), rat anti-LYVE-1 [clone C1/8, generated previously (5)] or rat anti-perlecan (Abcam) or isotype-matched antibodies (Sigma), each at 10 lg ml À1 , overnight at 4°C. AlexaFluorâ488 and AlexaFluorâ568 conjugates (Molecular Probes and Invitrogen) and Cy5 conjugates (Chemicon and Millipore) were used for secondary detection (2 h at room temperature) before mounting in Vectashield (Vector Laboratories) and viewing on a confocal microscope (Radiance 2000; Bio-Rad Laboratories/Zeiss) with sequential scanning.
Cells
Primary HDLECs were prepared from freshly resected skin samples by immunoselection with LYVE-1 mAb and MACSâ beads (Miltenyi Biotec), as previously described (5) . Cells were cultured in EGM-2MV media (Lonza), using plastic tissue culture flasks that had been precoated with 0.1% gelatin (Sigma). All experiments were performed with confluent cell cultures and, where indicated, were stimulated with recombinant human TNFa (2 ng ml À1 ; R&D Systems). PBMCs were obtained from healthy donors, and monocytes were purified by positive selection using anti-CD14-conjugated magnetic microbeads (Miltenyi Biotec). Monocyte-derived dendritic cells (MDDC) were generated by culturing monocytes for 5 days in RPMI-10% FCS supplemented with 50 ng ml À1 granulocyte macrophage colony-stimulating factor and 10 ng ml À1 IL-4 (R&D Systems) and matured with LPS (1 lg ml
À1
) from Salmonella abortus (Sigma-Aldrich). For fluorescent labelling, MDDC were incubated with 2.5 lM Cell Tracker Green (Invitrogen) in EGM-2MV media for 40 min and then washed in media and rested for 30 min prior to use in transmigration assays as described below.
Immunofluorescence antibody staining of cells HDLEC grown in culture were fixed in PFA (1% w/v in PBS, pH 7.4); incubated with mouse anti-CCL21 mAb (R&D Systems), polyclonal rabbit anti-LYVE-1 [generated previously (21) ], sheep anti-von Willebrand factor (vWf) (Serotec) or with isotype-matched IgG as appropriate (Sigma), 10 lg ml 
CCL21 ELISA
Supernatants and cell lysates from triplicate wells of confluent primary HDLEC were assayed for CCL21 using a commercial antigen capture ELISA method (DuoSet; R&D Systems), in accordance with the manufacturer's instructions. Briefly, supernatants were either applied directly to the ELISA in triplicate (as in Fig. 4 ) or concentrated using Amiconâ Ultra 0.5-ml centrifugation tubes, 5 kDa MW membrane (Millipore), before applying to the ELISA (as in Fig. 5 ). Adherent cells from the triplicate wells were lysed in lysis buffer [50 mM Tris, pH 7.4, 100 mM NaCl and 1% NP-40 (v/v), 1 mM EDTA and protease inhibitor cocktail (Roche)] and then applied to the ELISA in duplicate. Recombinant human CCL21 standards, in duplicate, and a negative control of EGM-2MV alone were applied alongside the samples. Bound CCL21 was detected using a secondary HRP-conjugated antibody and substrate for measurement in a microplate reader at 490 nm.
Western blotting
For analysis of CCL21 in primary HDLEC cultured in either the presence or the absence of TNFa, cells were lifted in 5 mM EDTA in PBS with protease inhibitor cocktail (Roche), then precipitated with trichloroacetic acid, 5% (w/v), washed in acetone and re-suspended in NuPAGE LDS sample buffer (Invitrogen). Samples were electrophoresed on Bis-Tris 4-12% polyacrylamide SDS gels (NuPAGE; Invitrogen) with MES buffer, alongside known amounts of recombinant human CCL21 (R&D Systems) and SeeBlue standard (Invitrogen). Protein was transferred to nitrocellulose membranes (Hybond-C Extra; Amersham Biosciences) and incubated with goat anti-CCL21 polyclonal antibody, 0.2 lg ml À1 (R&D Systems), in PBS, 5% (w/v) dried milk powder and 0.2% (v/v) Tween 20. Blots were developed with peroxidase-conjugated anti-goat Ig and visualized by chemiluminescence detection (SuperSignal; Pierce).
Lymphatic endothelial transmigration assays
Primary HDLECs were seeded onto the underside of gelatincoated FluoroBlok TM cell culture inserts (3-lm pore size; BD Biosciences), incubated for 2 h at 37°C and then placed in a companion plate (BD Biosciences) containing EGM-2MV medium. Cells were cultured until confluent and, where indicated, stimulated with TNFa (2 ng ml
À1
, R&D Systems), 24 h before use.
To assess MDDC transmigration in response to exogenous chemokine, CCL21 (25 ng ml
) was added to the HDLEC monolayers as appropriate, 2 h prior to the addition of 0.5 3 10 6 fluorescently labelled MDDC. Numbers of MDDC transmigrating through the filter and monolayer into the lower chamber were recorded at 30-min interval on an automated fluorescent multiprobe plate reader (Synergy HT; Bio-Tek) at 37°C using KC 4 software (Biotech). Fluorescence emission was calibrated against a standard curve, and transmigration was expressed as the number of MDDC in the lower chamber.
To assess the contribution of endogenous CCL21 to transmigration, MDDC were pre-incubated for 30 min in the presence of goat anti-human CCL21-neutralizing antibodies (40 lg ml À1 , R&D Systems), prior to the transmigration assay, with the neutralizing antibodies present throughout the procedure.
To assess the effect of blocking G-protein-coupled receptors, MDDC were pre-incubated for 2 h with pertussis toxin (200 ng ml À1 ; Calbiochem), in the presence of 25 mM HEPES (pH 7.4), washed in EGM-2MV and then applied to the HDLEC monolayer.
To investigate the involvement of b2 integrins in transmigration, the neutralizing mAb TS1/18 was used (50 lg ml À1 ) and migration assessed after 16 h, when any shear forceinduced integrin activation due to re-suspending/pipetting MDDC had subsided (22) .
Measurement of DC b2 integrin activation
The effects of CCL21 treatment on integrin activation status were assessed in MDDC by flow cytometry with the b2 integrin antibodies YFC118.3 (BD Pharmingen) and mAb 24 (a kind gift from Prof Nancy Hogg), which is conformation specific (23) .
For staining with YFC118.3, triplicate samples of MDDC were pre-incubated (2 h) in either RPMI-10% FCS alone or with recombinant human CCL21 (25 ng ml
À1
) and then Expression of CCL21 in inflamed lymphatics 841 re-suspended and incubated for 30 min at 5°C in PBS, pH 7.5, 5% FCS and 0.1% azide with either YFC118.3 (10 lg ml À1 ) or irrelevant rat IgG. Cells were then washed and incubated for 30 min at 5°C with goat anti-rat IgG-488 AlexaFluorâ.
For staining with mAb 24, MDDC (in triplicate) were preincubated with either CCL21 (25 ng ml À1 ) or in RPMI-10% FCS alone, 6 EDTA (5 mM), and then incubated for 20 min with either mAb 24 or mouse IgG1 (10 lg ml À1 ). Cells were washed briefly in incubation buffer and then fixed in 2% formaldehyde (v/v) (to prevent activation of integrins by centrifugation). Cells were washed again in incubation buffer and then incubated with goat anti-mouse IgG1-488 AlexaFluorâ. In each case, cells were analysed by flow cytometry (FACSCalibur; BD Biosciences) using CellQuest software. Images were quantitatively analysed using Image J software [National Institutes of Health (NIH), Bethesda, MD, USA].
Results
CCL21 is inducible within LYVE-1 + lymphatic endothelium of inflamed mouse dermis
To assess CCL21 expression in lymphatic endothelium, we performed dual immunostaining of mouse dermal tissue for analysis by fluorescence microscopy. As shown in Fig. 1(A) , CCL21 was detected at low levels within resting LYVE-1 + lymphatics in normal skin, distributed among small punctate structures. By comparison, in explanted TNFa-treated skin samples, the levels of CCL21 in such vessels were greatly increased (Fig. 1A) . Similar up-regulation of CCL21 was observed within LYVE-1 + dermal lymphatics of BALB/c mice exposed to oxazolone-induced skin contact hypersensitivity (25, 26) , in comparison with untreated controls (Fig. 1B) . The possibility of non-specific staining was ruled out by carrying out isotype-matched staining controls (Supplementary Figure 1 is available at International Immunology Online). Moreover, increased expression of CCL21 was also measured quantitatively, using image analysis software (Image J; NIH) to calculate the mean fluorescence intensity of CCL21 staining in images captured from multiple animals (Fig. 2) . Up-regulation of CCL21 was accompanied by an inflammation-induced reduction in LYVE-1 expression, as reported previously (24) . Crucially, however, no significant change in lymphatic density (shown by podoplanin staining, Fig. 2; Supplementary Figure 2 is available at International Immunology Online) was measured in this acute inflammation. These results confirm earlier morphology-based studies and underline the inducible nature of CCL21 expression in dermal lymphatics.
Regulation of CCL21 synthesis in primary HDLEC
To permit a more detailed analysis of CCL21 induction, we carried out experiments using primary HDLECs isolated by MACSâ bead selection using a mouse anti-LYVE-1 mAb. Importantly, these cells retained the surface phenotype of native lymphatic endothelium even after relatively extended culture (up to 18 passages from resection) as assessed by immunostaining and flow cytometry [(5, 24) and data not shown] for the lymphatic markers podoplanin (27) , Prox-1 (28, 29) , LYVE-1 (21, 30) and the pan-endothelial marker CD31 (31) . In addition, the immunoselected HDLECs were negative for both CD44 (a marker of fibroblasts, blood endothelial cells and late-passage HDLEC) and the blood vascular endothelial marker Pal-E (12).
Immunostaining of early passage HDLEC monolayers for CCL21 indicated that little or none of the chemokine was present at the cell surface (Fig. 3) . Likewise, no CCL21 was detected on the surface of HDLEC that had been detached from the monolayer and stained in suspension, or when the underlying matrix was examined, eliminating the possibility that the chemokine was targeted to the undersurface of the endothelium or sequestered on heparan sulphate proteoglycans (data not shown). However, after permeabilization of the monolayers with saponin, significant levels of intracellular CCL21 were detected within discrete vesicles beneath the plasma membrane and adjacent to the nucleus (Fig. 3) . In marked contrast to this pattern, considerable levels of CCL21 were detected on the surface of HDLEC that had been treated with TNFa, indicating cytokine-induced mobilization from intracellular stores. A previous study detected a high-affinity glycosylation-dependent interaction between podoplanin and CCL21 (32) . Furthermore, the authors demonstrated that podoplanin-CCL21 complexes can form on the basal cell membrane of lymphatic endothelia, and thus, this interaction may explain the retention of CCL21 on the cell surface of TNFa-stimulated HDLEC, which we observe in this current study (Fig. 3) . Curiously, the punctate pattern of CCL21 observed in lymphatic vessels in vivo was not apparent in HDLEC in vitro, possibly due to differences in expression of extracellular matrix proteins such as perlecan, abundantly expressed around lymphatic capillaries (Supplementary Figure 2 is available at International Immunology Online), which may affect distribution of chemokines.
Next, we estimated the levels of CCL21 secretion from HDLEC monolayers using ELISA. The results (Fig. 4) showed that unstimulated early passage cells secreted only residual levels of CCL21 into the culture medium (<50 pg ml À1 ). However, following incubation with TNFa, the level of CCL21 secretion increased almost 5-fold (250 pg ml À1 ). Curiously, when these measurements were repeated using later passage HDLEC (i.e. passage 5 ex vivo and above), the levels of CCL21 secretion were elevated even in unstimulated cells (200 pg ml À1 ) and little or no further increase was seen in response to TNFa treatment (Fig. 4) . This culture-induced change in CCL21 secretion by HDLEC indicates an early loss of regulatory control for chemokine action following removal of lymphatic vessels from their native tissue environment (12) . Consequently, all experiments described in this manuscript were carried out on early passage HDLEC of passage 4 or less.
TNFa triggers HDLEC CCL21 secretion via de novo RNA synthesis
To establish the relationship between intracellular (i.e. stored) and secreted CCL21 in HDLEC and determine whether synthesis is regulated at the level of transcription or translation, we pre-treated cells with either the protein synthesis inhibitor cycloheximide (CHX) or the inhibitor of RNA transcription actinomycin-D (ActD), prior to separate estimation of secreted and cell-associated CCL21 by ELISA. The results (Fig. 5A) showed that CHX treatment had a strongly suppressive effect on CCL21 secretion from unstimulated HDLEC and potently inhibited CCL21 secretion from TNFa-treated cells, whereas actinomycin-D selectively inhibited TNFa-induced CCL21 secretion. In contrast, both + lymphatic vessels. Mouse ear explants were cultured in the presence of TNFa and then subjected to whole-mount staining for CCL21 (red) and LYVE-1 (green), in parallel to freshly resected mouse ear tissue (control). (A) Whole-mount staining was also performed on ears removed from mice sensitized to oxazolone, comparing ear tissue following the induction of inflammation with the contralateral ear that had received vehicle alone. (B) The presence of vessels exhibiting reduced expression of LYVE-1 indicates exposure to pro-inflammatory cytokines and inflammation (24) . Representative images from five mice are shown in each case (bar = 10 lm).
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agents elicited only modest reductions in the level of cell-associated CCL21 (i.e. plasma membrane and intracellular vesicle-bound chemokine) as estimated by ELISA of detergent lysates and fluorescent staining of saponin-permeabilized HDLEC monolayers ( Fig. 5B and C) . Moreover, the steady-state level of total cell-associated CCL21 appeared to be largely unchanged after TNFa treatment, as shown by western blotting (Fig. 5D ). Taken together, these results indicate that TNFa induces de novo synthesis of CCL21 via transcriptional up-regulation and that the newly synthesized chemokine is specifically targeted for rapid secretion. CCL21 does not co-localize with vWf in HDLEC, either resting or following 24-h TNFa stimulation ( Supplementary Figure 3 is available at International Immunology Online), suggesting that this chemokine is not stored in Weibel-Palade bodies for rapid secretion in the absence of de novo synthesis, unlike other chemokines, such as IL-8 (33).
CCL21 promotes transmigration of DC across lymphatic endothelium in vitro
To assess whether CCL21 can trigger lymphatic transmigration of DC as distinct from its effects on tropism, we measured in vitro basolateral-to-luminal transit of LPS-matured MDDC across monolayers of resting or TNFa-activated HDLEC plated on the undersurface of transwell FluoroBlok TM membranes [described previously in ref. (5)]. First, we examined the effects on transmigration of directly adding exogenous CCL21 to the assay. As shown in Fig. 6 , the addition of the chemokine significantly enhanced the rate of DC transmigration across both TNFa-activated (Fig. 6A) and resting (Fig. 6B) HDLEC monolayers. Moreover, the enhanced transmigration was ablated in each case by inclusion of pertussis toxin (Fig. 6A-C) , providing confirmation that the observed effects of CCL21 were mediated through binding its G i protein-coupled receptor.
Next, we determined the extent to which endogenous HDLEC-derived CCL21 contributed to DC transmigration, by inducing blockade with a CCL21-neutralizing mAb. As shown in Fig. 6(D) , CCL21 neutralization markedly reduced DC migration across unstimulated HDLEC and had a moderate and more transient effect on migration across TNFa-treated HDLEC. The apparent reduction in chemokine dependency in activated HDLEC may reflect the primacy of CAM-mediated events in such cells compared with resting HDLECs when tested in this static assay system or alternatively imply the involvement of additional chemokines in the process.
CCL21 induces activation of b2 integrins in DC
It has been well documented that CCL21 promotes transmigration of T cells across vascular endothelium by inducing clustering and transient activation of b2 integrins (18) . As b2 integrins and their primary endothelial ligand ICAM-1 have been shown to mediate leucocyte transmigration across lymphatic endothelium (5), we asked whether integrin activation by CCL21 was also induced in DC. As shown in Fig. 7 , exposure of MDDC to CCL21 indeed led to an increase in reactivity for the antibody mAb 24 that recognizes a divalent cation-dependent epitope in the active conformation of the b2 integrin subunit (23) , whereas reactivity to the pan-reactive b2 integrin mAb YFC118.3 remained unchanged.
The notion that DC employ integrin-dependent adhesion for interstitial chemotaxis and translymphatic migration was challenged in a recent study, which found that when pan integrin-deficient DC and wild-type DC were co-injected into the footpads of mice, both migrated to the lymph nodes with equal efficiency (19) . However, these findings were obtained under steady-state conditions, as opposed to previous studies that had found an involvement for integrins and their CAM receptors in inflammatory conditions (5, (34) (35) (36) . Therefore, we attempted to resolve this issue by examining the effect of blocking b2 integrin on MDDC transmigration across both resting and TNFa-stimulated HDLEC. As shown in Fig. 8 , blockade with the b2 integrin mAb TS1/18 had no effect on migration across resting HDLEC. However, the TS1/18 mAb effectively blocked MDDC transmigration across TNFa-treated HDLEC, reducing the level to that of resting monolayers. These data support the view that constitutive migration across lymphatic endothelium does not require integrin involvement. Importantly, they also show that in TNFa-stimulated HDLEC, enhanced secretion of CCL21 activates b2 integrins, which are subsequently required for mediating increased migration of DC.
Discussion
In this manuscript, we have presented new data on the nature of CCL21 synthesis in lymphatic endothelium and the mechanisms by which the chemokine promotes recruitment of DC via a lymphatic route from the tissues to the lymph nodes. Despite the fact that previous reports have implied Mouse ear explants were cultured in the presence of TNFa and then subjected to whole-mount staining for CCL21, LYVE-1 and podoplanin, in parallel to freshly resected mouse ear tissue (control). The mean fluorescence intensity of staining was measured using Image J software, from a total of 21 images, all captured using the same confocal laser settings. Data are the mean 6 SEM. CCL21 and LYVE-1 staining was significantly different between TNFa and control samples, *P < 0.05%, Mann-Whitney statistical test, while podoplanin staining was not significantly different.
that CCL21 is critical for exit of DC from the tissues through afferent lymphatics, it has not been clear whether the chemokine controls primarily interstitial migration or intraluminal crawling or whether it triggers adhesion and transmigration of lymphatic vessel endothelium-a step that only recently has been recognized as a regulatory point for lymph node trafficking during initiation of the immune response (6). Specifically in the mouse, where separate isoforms of CCL21 (CCL21 Ser and CCL21 Leu ) are expressed in lymphoid tissue and peripheral lymphatics, respectively, selective ablation of the former disrupted accumulation of dermis-derived DC in lymph nodes but appeared to leave exit from the tissues through the peripheral lymphatics intact. Here, we have focused on the lymphatic endothelium and specifically on primary HDLEC to investigate the regulation of CCL21 expression and to directly assess its role in lymphatic transmigration.
Using the hyaluronan receptor LYVE-1 as a marker of lymphatic endothelium in mouse dermis, we provided rigorous confirmation that CCL21 is expressed constitutively by small lymphatic vessels and that synthesis is increased markedly in response to inflammation, such as that induced by the sensitizing agent oxazolone. Moreover, using cultured primary HDLEC, we showed that TNFa promotes CCL21 secretion through an increase in RNA and protein synthesis, thus substantiating previous indirect evidence that CCL21 is both constitutive and inducible and has features of both a homeostatic and an inflammatory chemokine in this cell type.
The level of induction of CCL21 in response to TNFa was found to vary, depending upon the passage number of primary HDLEC. Measurements of in vivo CCL21 expression levels in resting and activated lymphatic vessels (determined by fluorescence microscopic imaging in Fig. 2 ) revealed an ;2-fold increase in expression of cellassociated chemokine, although secreted chemokine could not be detected by this method. In vitro studies revealed an induction of secreted CCL21 of up to 20-fold, as opposed to a less dramatic increase in later passage cells. The earlier Expression of CCL21 in inflamed lymphatics 845 passage HDLEC could be expected to resemble native lymphatic endothelia more closely.
Most notably, using an in vitro assay with primary HDLEC that approximates the basolateral-luminal passage of DC in tissue lymphatics, we demonstrated for the first time that exogenously added CCL21 promotes transmigration of mature DC. Furthermore, we showed that a CCL21-neutralizing antibody inhibited DC transmigration across resting HDLEC monolayers and significantly retarded migration across TNFa-treated monolayers. These findings highlight the quantitative importance of endogenously derived CCL21 for lymphatic trafficking under both homeostatic and inflammatory conditions and identify this chemokine as a key component in the active process of translymphatic migration. Our finding that CCL21 blockade had a less marked effect in activated HDLEC is indicative that other chemokines are also In keeping with the known action of chemokines, such as IL-8, it would seem most likely that CCL21 would promote DC transmigration via conformational activation of b2 integrins followed by adhesion to endothelial ICAMs (18) . Our data support this view insofar as they showed that exposure of MDDC to CCL21 results in enhanced reactivity with the activation-dependent b2 integrin mAb 24 and that the b2 integrin-blocking mAb TS1/16 specifically impairs the TNFainduced component of lymphatic transmigration. However, we also found that b2 integrins are not required for constitutive transmigration of MDDC across resting HDLEC. This latter finding resolves an important discrepancy in the literature. The 'conventional' mechanism of chemokine-induced transmigration triggered by integrin activation, CAM-mediated adhesion and diapedesis is supported by numerous reports, which demonstrated that antibody blockade of the leucocyte integrin leucocyte function-associated antigen-1 (aLb2) or endothelial ICAM-1 inhibited trafficking of skin DC to draining lymph nodes following skin contact sensitization (34) (35) (36) . In addition, our own published evidence has shown that neutralizing mAbs to b2 integrins, ICAM-1 and VCAM-1 block DC adhesion and translymphatic migration both in vitro and in vivo (5) . Conversely, a recent study found that following co-injection into the footpads of mice, pan integrin-deficient DC and wild-type DC migrated to the lymph nodes with equal efficiency, unlike CCR7-deficient DC (19) . On the basis of Expression of CCL21 in inflamed lymphatics 847 their findings, these authors concluded that lymphatic entry requires no specific adherence events by DC and that the requirement for CCL21 was to facilitate tropism towards afferent lymphatic vessels via passive 'amoeboid-like' movement. Nevertheless, the key factor that must be taken into consideration is that the lymphatic trafficking experiments of this later study (19) were conducted with resting non-activated lymphatics, whereas the earlier studies involved exposure of lymphatic endothelium to inflammatory conditions (5, 34, 35) . The two sets of data can therefore be reconciled on the basis that different regulatory mechanisms almost certainly operate in each circumstance and that integrin-independent DC trafficking is most likely confined to uninflamed lymphatics. The data that are presented in this manuscript argue strongly in favour of CCL21-mediated transmigration being inextricably linked to adhesion-mediated events in activated lymphatics.
We conclude on the basis of data shown in this manuscript that inflammation-induced expression of CCL21 in lymphatics is linked to CAM-mediated adhesion and transmigration of DC, whereas constitutive expression of CCL21 appears to be linked to integrin-independent transmigration. Further understanding of these two different mechanisms may prove to be useful in targeting new lymphatic-based anti-inflammatory therapies. Supplementary Figures 1-3 
Supplementary data
